Zacks.com on MSN3d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
manilatimes4d
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...
BioPharma Dive5d
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Crispr Therapeutics: Poised For A Major Turnaround
Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...
Stockhouse14d
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ ... These forward-looking statements include statements about our business and growth strategy, ...
Yahoo News UK14d
Huge research and development facility next to M62 approved
A huge research and development facility is to be built in Rochdale ... READ MORE: Life in the Greater Manchester town with a TWELVE year housing wait Atom Valley is one of six growth locations in ...
Impacts15d
The Role of Vertex Pharmaceuticals in Boston’s Biotech Boom
The Impact of Vertex on Boston’s Biotech Scene: Contributions to research, job growth, and economy Vertex Pharmaceuticals has significantly transformed Boston’s biotech landscape. Their innovative ...
Business Insider16d
Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report ... Wang sees the potential for future growth but advises holding the stock ...
Investing17d
Rhythm Pharmaceuticals keeps stock target with Buy rating on joint research
On Thursday, H.C. Wainwright maintained a Buy rating and a $64.00 stock price target on Rhythm Pharmaceuticals (NASDAQ:RYTM). This affirmation follows the announcement of a joint research ...
Yahoo Finance17d
Recent 5.4% pullback isn't enough to hurt long-term Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders, they're still up 159% over 3 years
earnings-per-share-growth It might be well worthwhile taking a look at our free report on Vertex Pharmaceuticals' earnings, revenue and cash flow. Vertex Pharmaceuticals shareholders are up 31% ...
Investing17d
Vertex reveals promising kidney disease treatment results
BOSTON - Vertex Pharmaceuticals (NASDAQ ... This could be attributed to increased research and development expenses associated with advancing its kidney disease pipeline. However, the company's ...